Aptalis Sponsors AAPS Research Achievement Awards
Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, recently announced its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) and its participation in the 2012 AAPS Annual Meeting and Exposition October 14-18, 2012, in Chicago, IL.
The 2012 annual meeting and exposition is an international forum for the exchange of knowledge among an expected 9,000 attendees, including scientists working in drug design, discovery, development, delivery, packaging, scale-up, clinical trials, and regulatory sciences.
The AAPS Research Achievement Awards are intended to recognize outstanding scientists who have conducted fundamental research that has had significant impact in the fields of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism. PPDM is the section of the AAPS that provides an opportunity for the presentation of new data and an exchange of ideas by individuals actively engaged in the various facets of pharmacokinetics, pharmacodynamics, drug metabolism, transport, biopharmaceutics, and related sciences. Meeting participants are invited to visit the Aptalis Pharmaceutical Technologies’ poster presentation: T2132, Development of Orally Disintegrating Tablets Comprising Controlled-Release Multiparticulate Beads, by P.J. Stevens, G. Venkatesh, J. Lai, October 16, 2012, Hall F, McCormick Place 9:30 AM to 12:30 PM and to visit the Aptalis Career Center Booth No. CC1.
Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release, Bioavailability Enhancement, and Taste Masking for ODTs (orally disintegrating tablets) and other dosage forms. Together, these technology platforms combined with licensing, manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability. Aptalis Pharmaceutical Technologies develops and manufactures products for its partners, as well as supports the drug development process for the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis Pharmaceutical Technologies, visit www.AptalisPharmaTech.com.
Total Page Views: 848
